Brief: Royalty Pharma To Acquire Royalty Interest In Sanofi’S Frexalimab
09/05/2024 12:48
May 9 (Reuters) - Royalty Pharma PLC RPRX.O :
* ROYALTY PHARMA TO ACQUIRE ROYALTY INTEREST IN SANOFI’S
FREXALIMAB
* ROYALTY PHARMA : PROPOSED DEAL FOR APPROXIMATELY $525
MILLION IN
CASH
* ROYALTY PHARMA : EXPANDS CO'S DEVELOPMENT-STAGE PORTFOLIO
TO 15
THERAPIES WITH COMBINED POTENTIAL TO GENERATE GREATER THAN $1
BILLION IN ANNUAL ROYALTIES
Source text for Eikon: ID:nGNX7qzqBz
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)